Economic assessment of TELEGRAFT

The problems are particularly significant when the artificial blood vessels are used for dialysis, where up to 70 percent of the blood vessels close or become infected within a year.

AIM

TELEGRAFT (Telemonitoring of home dialysis utilising a smart biomimetic arteriovenous graft) will develop an artificial, innovative blood vessel, designed to minimise the risk of closure and infection, thus significantly reducing complications.

Traditionally, complications are often only discovered when they have become critical, but the innovative nature of TELEGRAFT, together with a smart telemonitoring system, will increase the possibilities for early intervention. This new approach has the potential to reduce both patient suffering and healthcare costs.

The artificial vein can make dialysis safer and faster, and if the project is successful in developing the vein, dialysis patients will be able to use home dialysis in the long term and thus save time traveling back and forth to the hospital 2-3 times a week. The technology will also be easily and quickly used for, for instance, bypass operations.

When TELEGRAFT is fully developed and has undergone animal testing, it will be tested in an international study with participants from Denmark, Sweden, Lithuania, Germany and Spain.

PARTNERS

The project is administered and coordinated by the University of Southern Denmark.

In addition, the Region of Southern Denmark, the Region of Stockholm, Verigraft, Biomodics, Leibniz Institute of Photonic Technology, Vilnius University Hospital, BMD Software, Technischen Universität München, Servicio Vasco de Salud Osakidetza and University of Birmingham are partners on the project.

CIMT will be in charge of an economic assessment of the project.

EXTERNAL FUNDING

The project is financed by the British government, OUH and SDU. In addition, the project has been granted €5.362.620 from the EU's Horizon Europe funding programme.